Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...

Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...

BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...

Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...

The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.  According to ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Sino American biotech BeiGene has announced financial results and corporate updates from the fourth quarter and full year ...